Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

Company Overview - Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections using proprietary technology [3]. Upcoming Presentation - Dr. Mina Pastagia, Chief Medical Officer of Armata, will present at the 6th Annual Bacteriophage Therapy Summit on February 28, 2024, covering the clinical trials and advantages of Armata's bacteriophage candidates [1]. - The presentation will include topics such as the multi-phage cocktail approach for chronic Pseudomonal respiratory infections and the safety of intravenous dosing of Armata's S. aureus phage candidate [1]. Industry Context - The 2024 Bacteriophage Therapy Summit aims to optimize safety, efficacy, and manufacturing of next-generation bacteriophage therapies, with a focus on demonstrating positive clinical data and patient outcomes [2]. - The summit will feature over 90 phage experts and is positioned as a global platform for phage drug developers, emphasizing advancements in clinical and regulatory development, manufacturability, and innovative applications [2].